Loading…
Dextromethorphan Abuse Reduction Act of 2009
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,048 other S bills in the 111th — cohort avg 29d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (19)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
HR 452 - Medicare Decisions Accountability Act of 2011 S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011 Gene Therapy Personalized Medicine H.R.2245 Preserving Access to Life-Saving Medications Act of 2011 S.296 Preserving Access to Life-Saving Medications Act S.1206 Medicare Drug Savings Act of 2011 H.R.2190 Medicare Drug Savings Act of 2011 Section 9008 of Patient Protection and Affordable Care Act Prescription Drug User Fee Act (PDUFA) H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Public Health Service Act Dextromethorphan - Age Restrictions - Controlling bulk shipments Pseudoephedrine - Promote e-tracking; oppose Rx legislation FSA/HSA - Support reinstating coverage of OTC products Enhance supply and shipping parameters for beta-Propiolactone Support incentives for development of new, innovative antibiotics (former GAIN Act) MDUFA
Client expense: $1,902,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
HR 452 - Medicare Decisions Accountability Act of 2011 S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011 Gene Therapy Personalized Medicine H.R.2245 Preserving Access to Life-Saving Medications Act of 2011 S.296 Preserving Access to Life-Saving Medications Act S.1206 Medicare Drug Savings Act of 2011 H.R.2190 Medicare Drug Savings Act of 2011 Section 9008 of Patient Protection and Affordable Care Act Prescription Drug User Fee Act (PDUFA) H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Public Health Service Act Dextromethorphan - Age Restrictions - Controlling bulk shipments Pseudoephedrine - Promote e-tracking; oppose Rx legislation FSA/HSA - Support reinstating coverage of OTC products Enhance supply and shipping parameters for beta-Propiolactone Support incentives for development of new, innovative antibiotics (former GAIN Act) MDUFA
Client expense: $1,129,000 · Firm income: Not reported
HR 452 - Medicare Decisions Accountability Act of 2011 S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011 Gene Therapy Personalized Medicine H.R.2245 Preserving Access to Life-Saving Medications Act of 2011 S.296 Preserving Access to Life-Saving Medications Act S.1206 Medicare Drug Savings Act of 2011 H.R.2190 Medicare Drug Savings Act of 2011 Section 9008 of Patient Protection and Affordable Care Act Prescription Drug User Fee Act (PDUFA) H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Public Health Service Act Dextromethorphan - Age Restrictions - Controlling bulk shipments Pseudoephedrine - Promote e-tracking; oppose Rx legislation FSA/HSA - Support reinstating coverage of OTC products Enhance supply and shipping parameters for beta-Propiolactone Support incentives for development of new, innovative antibiotics (former GAIN Act) MDUFA
Client expense: $1,631,812 · Firm income: Not reported
HR 452 - Medicare Decisions Accountability Act of 2011 S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011 Gene Therapy Personalized Medicine H.R.2245 Preserving Access to Life-Saving Medications Act of 2011 S.296 Preserving Access to Life-Saving Medications Act S.1206 Medicare Drug Savings Act of 2011 H.R.2190 Medicare Drug Savings Act of 2011 Section 9008 of Patient Protection and Affordable Care Act Prescription Drug User Fee Act (PDUFA) H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Public Health Service Act Dextromethorphan - Age Restrictions - Controlling bulk shipments Pseudoephedrine - Promote e-tracking; oppose Rx legislation FSA/HSA - Support reinstating coverage of OTC products Enhance supply and shipping parameters for beta-Propiolactone Support incentives for development of new, innovative antibiotics (former GAIN Act) MDUFA
Client expense: $1,918,136 · Firm income: Not reported
HR 452 - Medicare Decisions Accountability Act of 2011 S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011 Gene Therapy Personalized Medicine H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Public Health Service Act Dextromethorphan - Age Restrictions - Controlling bulk shipments Pseudoephedrine - Promote e-tracking; oppose Rx legislation FSA/HSA - Support reinstating coverage of OTC products Enhance supply and shipping parameters for beta-Propiolactone Support incentives for development of new, innovative antibiotics (former GAIN Act) MDUFA
Client expense: $1,650,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,000,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
2010 · second_quarter · Pharmacy
H.R. 1204, the Community Pharmacy Fairness Act of 2009 and S. 2191, the Community Pharmacy Fairness Act from the 110th Congress; H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2010 and working on Senate companion; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; H.R. 6331 (110th Congress), the Medicare Improvement for Patients and Providers Act of 2008-Sec. 172 related to the implementation of the Medciare Part D prompt pay requirements and submission of claims by pharmacies located in or contracting with long-term care facilities; H.R. 5235, the Medicare Access to Diabetic Supplies Act of 2010 and working on Senate companion; H.R. 3790, legislation to eliminate the Medicare Part B DME competitive bidding program; H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010-advocated for inclusion of the extension of the Federal Medicaid Matching Rate (FMAP) and limiting access to 340b drugs in outpatient settings to only eligible individuals in both House bill and Senate amendment; H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions related to pedigree and track and trace requirements-no bill introduced in the current Congress; H.R. 5136 and S. 3454, the FY11 National Defense Authorization Act , includes funding for the Department of Defense FY11 budget and covers the TRICARE pharmacy program; H.R. 3108 and S. 3543, the Medication Therapy Management Expanded Benefit Act; H.R. 2923, the Combat Meth Act of 2009; S. 1383, the Dextromethorphan Abuse Reduction Act of 2009; submitted comments to Senate Committee on Aging on prescription drug disposal and the role of nurses as agents in long-term care facilities; sought Congressional support to stop exclusion of certain retail pharmacies from "employee prescription drug plans;" worked with Congressional offices to request the FTC review the 180 day generic drug marketing exclusivity policies of certain generic manufacturers; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); submitted comments to Senate Judiciary Committee regarding the FTC and DOJ antitrust oversight; submitted comments to Senate Homeland Security and Government Affairs Committee regarding a HHS OIG report, "Invalid Prescriber Identifiers on Medicare Part D Drug Claims;" FSA debit card program-seeking Congressional support to amend IRS guidance (no legislation).
Client expense: $106,568 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
2010 · second_quarter · Pharmacy
H.R. 1204, the Community Pharmacy Fairness Act of 2009 and S. 2191, the Community Pharmacy Fairness Act from the 110th Congress; H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2010 and working on Senate companion; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; H.R. 6331 (110th Congress), the Medicare Improvement for Patients and Providers Act of 2008-Sec. 172 related to the implementation of the Medciare Part D prompt pay requirements and submission of claims by pharmacies located in or contracting with long-term care facilities; H.R. 5235, the Medicare Access to Diabetic Supplies Act of 2010 and working on Senate companion; H.R. 3790, legislation to eliminate the Medicare Part B DME competitive bidding program; H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010-advocated for inclusion of the extension of the Federal Medicaid Matching Rate (FMAP) and limiting access to 340b drugs in outpatient settings to only eligible individuals in both House bill and Senate amendment; H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions related to pedigree and track and trace requirements-no bill introduced in the current Congress; H.R. 5136 and S. 3454, the FY11 National Defense Authorization Act , includes funding for the Department of Defense FY11 budget and covers the TRICARE pharmacy program; H.R. 3108 and S. 3543, the Medication Therapy Management Expanded Benefit Act; H.R. 2923, the Combat Meth Act of 2009; S. 1383, the Dextromethorphan Abuse Reduction Act of 2009; submitted comments to Senate Committee on Aging on prescription drug disposal and the role of nurses as agents in long-term care facilities; sought Congressional support to stop exclusion of certain retail pharmacies from "employee prescription drug plans;" worked with Congressional offices to request the FTC review the 180 day generic drug marketing exclusivity policies of certain generic manufacturers; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); submitted comments to Senate Judiciary Committee regarding the FTC and DOJ antitrust oversight; submitted comments to Senate Homeland Security and Government Affairs Committee regarding a HHS OIG report, "Invalid Prescriber Identifiers on Medicare Part D Drug Claims;" FSA debit card program-seeking Congressional support to amend IRS guidance (no legislation).
Client expense: $106,568 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,000,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
2010 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 1259, Dextromethorphan Distribution Act of 2009; S. 1383, Dextromethorphan Abuse Reduction Act of 2009
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Consumer Issues/Safety/Products
Importation H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09 H.R. 573 - Act to Prohibit the Marketing of Authorized Generic Drugs, 1/09
Client expense: $2,590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2010 · fourth_quarter · Alcohol and Drug Abuse
HR 1259 & S 1383 - Dextromethorphan Abuse S 256 & HR 2923 - Methamphetamine Abuse Issues related to methamphetamine precursor chemicals
Client expense: $715,571 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Office of Natl Drug Control Policy (NDCP), SENATE, Treasury, Dept of
2010 · fourth_quarter · Consumer Issues/Safety/Products
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications. - H.R. 2923, "A bill to Enhance the ability to combat Methamphetamine", regarding all provisions. - H.R. 5786, "Safe Cosmetics Act of 2010", regarding all provisions.
Client expense: $850,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2010 · fourth_quarter · Consumer Issues/Safety/Products
H.R.1259, Dextromethorphan Distribution Act of 2009; S.1383, Dextromethorphan Abuse Reduction Act of 2009; Issues related to preventing the abuse of prescription and nonprescription drugs.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Pharmacy
H.R.1259 Dextromethorphan Distribution Act of 2009; S. 1383 Dextromethorphan Abuse Reduction Act of 2009
Client expense: $980,915 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2010 · fourth_quarter · Health Issues
Health care reform law (PL 111-148): implementation issues. FDA oversight of Laboratory-Developed Tests (LDTs). S. 1383, The Dextromethorphan Abuse Prevention Act of 2009
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2010 · fourth_quarter · Alcohol and Drug Abuse
HR 1259, Dextromethorphan Distribution Act, restrictions on distribution of bulk Dextromethorphan. S. 1383, Dextromethorphan Abuse Reduction Act of 2009; Amendment to Controlled Substances Act to prevent abuse of Dextromethorphan and to impose age restrictions. Electronic tracking for pseudoephedrine - No bills.
Client expense: Not reported · Firm income: $30,000
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Consumer Issues/Safety/Products
H.R. 1259, Dextromethorphan Distribution Act of 2009; S. 1383, Dextromethorphan Abuse Reduction Act of 2009
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Consumer Issues/Safety/Products
Importation H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09 H.R. 573 - Act to Prohibit the Marketing of Authorized Generic Drugs, 1/09
Client expense: $4,150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2010 · third_quarter · Pharmacy
H.R. 1359 Secure and Responsible Drug Disposal Act of 2009; H.R. 1191 Safe Drug Disposal Act of 2009; H.R.1259 Dextromethorphan Distribution Act of 2009; S. 1383 Dextromethorphan Abuse Reduction Act of 2009
Client expense: $1,030,211 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2010 · third_quarter · Consumer Issues/Safety/Products
HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug Safety provisions relating to country of origin labeling for drugs and devices. S. 1383 the Dextromethorphan Abuse Reduction Act of 2009 all provisions; regarding amending the Controlled Substances Act to prevent the abuse of dextromethorphan.
Client expense: $340,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Consumer Issues/Safety/Products
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications. - H.R. 2923, "A bill to Enhance the ability to combat Methamphetimine", regarding all provisions. - H.R. 5786, "Safe Cosmetics Act of 2010", regarding all provisions.
Client expense: $2,410,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2010 · third_quarter · Alcohol and Drug Abuse
HR 1259 & S 1383 - Dextromethorphan Abuse S 256 & HR 2923 - Methamphetamine Abuse Issues related to methamphetamine precursor chemicals
Client expense: $736,734 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Office of Natl Drug Control Policy (NDCP), SENATE
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,842,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
2010 · third_quarter · Consumer Issues/Safety/Products
H.R.1259, Dextromethorphan Distribution Act of 2009; S.1383, Dextromethorphan Abuse Reduction Act of 2009; Issues related to preventing the abuse of prescription and nonprescription drugs.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Alcohol and Drug Abuse
HR 1259, Dextromethorphan Distribution Act, restrictions on distribution of bulk Dextromethorphan. S. 1383, Dextromethorphan Abuse Reduction Act of 2009; Amendment to Controlled Substances Act to prevent abuse of Dextromethorphan and to impose age restrictions. Electronic tracking for pseudoephedrine - No bills.
Client expense: Not reported · Firm income: $30,000
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Pharmacy
H.R. 1204, the Community Pharmacy Fairness Act of 2009; H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2010 and working on Senate companion; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; working with Senate Committee on Health, Education, Labor and pensions on a potential hearing; working with House Committee on Energy and Commerce (health subcommittee) on a potential hearing; worked with the Senate Committee on Aging to provide information for an ongoing committee investigation of certain retail pharmacy practices; H.R. 5235, the Medicare Access to Diabetes Supplies Act of 2010 and working on Senate companion; H.R. 3790, legislation to eliminate the Medicare Part B DME competitive bidding program; submitted statement for the House Committee on Energy and Commerce hearing on the Part B DME competitive bidding program; H.R. 1586, the Education Jobs and Medicaid funding bill, which included an extension of FMAP and change to the AMP definition and became law on 8/10/2010; H.R. 5136 and S. 3454, the FY11 National Defense Authorization Act, includes funding for the Department of Defense and covers the TRICARE pharmacy program; H.R. 3108 and S. 1383, the Medication Therapy Management (MTM) Expanded Benefit Act; worked with Senate offices to gain support for the implemenation of an authpirzed grant program for MTM services; worked with Senate Aging Committee on the issue of nurses as agents in long-term care facilties; H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010 (NASPER); H.R. 5809, the Safe Drug Disposal Act and S. 3397, the Secure & Responsible Drug Disposal Act (became law 10-12-10); worked with Congressional offices on the issue of Medicare Part B recoupment by CMS; sough Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); worked with Congressional offices in seeking clarification from the Department of Treasury regarding the new "over the counter" rules with Flexible Spending Accounts (FSA).
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA), Treasury, Dept of
2010 · second_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 882 - Drug and Device Accountability Act H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $2,250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2010 · second_quarter · Consumer Issues/Safety/Products
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346/ S. 540, "Medical Device Safety Act of 2009", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications.
Client expense: $1,150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2010 · second_quarter · Pharmacy
H.R. 1204, the Community Pharmacy Fairness Act of 2009 and S. 2191, the Community Pharmacy Fairness Act from the 110th Congress; H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2010 and working on Senate companion; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; H.R. 6331 (110th Congress), the Medicare Improvement for Patients and Providers Act of 2008-Sec. 172 related to the implementation of the Medciare Part D prompt pay requirements and submission of claims by pharmacies located in or contracting with long-term care facilities; H.R. 5235, the Medicare Access to Diabetic Supplies Act of 2010 and working on Senate companion; H.R. 3790, legislation to eliminate the Medicare Part B DME competitive bidding program; H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010-advocated for inclusion of the extension of the Federal Medicaid Matching Rate (FMAP) and limiting access to 340b drugs in outpatient settings to only eligible individuals in both House bill and Senate amendment; H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions related to pedigree and track and trace requirements-no bill introduced in the current Congress; H.R. 5136 and S. 3454, the FY11 National Defense Authorization Act , includes funding for the Department of Defense FY11 budget and covers the TRICARE pharmacy program; H.R. 3108 and S. 3543, the Medication Therapy Management Expanded Benefit Act; H.R. 2923, the Combat Meth Act of 2009; S. 1383, the Dextromethorphan Abuse Reduction Act of 2009; submitted comments to Senate Committee on Aging on prescription drug disposal and the role of nurses as agents in long-term care facilities; sought Congressional support to stop exclusion of certain retail pharmacies from "employee prescription drug plans;" worked with Congressional offices to request the FTC review the 180 day generic drug marketing exclusivity policies of certain generic manufacturers; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); submitted comments to Senate Judiciary Committee regarding the FTC and DOJ antitrust oversight; submitted comments to Senate Homeland Security and Government Affairs Committee regarding a HHS OIG report, "Invalid Prescriber Identifiers on Medicare Part D Drug Claims;" FSA debit card program-seeking Congressional support to amend IRS guidance (no legislation).
Client expense: $106,568 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
2010 · second_quarter · Pharmacy
H.R. 1359 Secure and Responsible Drug Disposal Act of 2009; H.R. 1191 Safe Drug Disposal Act of 2009; H.R.1259 Dextromethorphan Distribution Act of 2009; S. 1383 Dextromethorphan Abuse Reduction Act of 2009; S. 256 Combat Methamphetamine Enhancement Act of 2009
Client expense: $1,079,067 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,616,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
2010 · second_quarter · Alcohol and Drug Abuse
HR 1259 & S 1383 - Dextromethorphan Abuse S. 256 & HR 2923 - Methamphetamine Abuse Issues related to methamphetamine precursor chemicals
Client expense: $1,687,444 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
2010 · second_quarter · Consumer Issues/Safety/Products
H.R.1259, Dextromethorphan Distribution Act of 2009; S.1383, Dextromethorphan Abuse Reduction Act of 2009; Issues related to preventing the abuse of prescription and nonprescription drugs.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Alcohol and Drug Abuse
HR 1259, Dextromethorphan Distribution Act, restrictions on distribution of bulk Dextromethorphan. S. 1383, Dextromethorphan Abuse Reduction Act of 2009; Amendment to Controlled Substances Act to prevent abuse of Dextromethorphan and to impose age restrictions. Electronic tracking for pseudoephedrine - No bills.
Client expense: Not reported · Firm income: $20,000
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Consumer Issues/Safety/Products
HR 1259 the Dextromethorphan Distribution Act of 2009 all provisions of the bill; regarding amending the federal food, drug, and cosmetic act to limit the distribution and abuse of DXM. HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug Safety provisions relating to country of origin labeling for drugs and devices. S. 1383 the Dextromethorphan Abuse Reduction Act of 2009 all provisions; regarding amending the Controlled Substances Act to prevent the abuse of dextromethorphan.
Client expense: $350,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
2010 · first_quarter · Consumer Issues/Safety/Products
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions.
Client expense: $2,110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2010 · first_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 882 - Drug and Device Accountability Act H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $4,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2010 · first_quarter · Law Enforcement/Crime/Criminal Justice
HR 1173, Organized Retail Crime Act of 2009 - Organized Retail Crime S. 470, Combating Organized Retail Crime Act of 2009 - Organized Retail Crime HR 1166, E-fencing Enforcement Act of 2009 - Organized Retail Crime S. 1383, Dextromethorphan Abuse Reduction Act H.R. 4011 Organized Retail Crime Prevention and Enforcement Act
Client expense: $280,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Federal Bureau of Investigation (FBI), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, Treasury, Dept of
2010 · first_quarter · Alcohol and Drug Abuse
HR 1259 & S 1383 - Dextromethorphan Abuse S. 256 & HR 2923 - Methamphetamine Abuse
Client expense: $423,644 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $2,040,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
2010 · first_quarter · Pharmacy
H.R. 1359 Secure and Responsible Drug Disposal Act of 2009; H.R. 1191 Safe Drug Disposal Act of 2009; H.R.1259 Dextromethorphan Distribution Act of 2009; S. 1383 Dextromethorphan Abuse Reduction Act of 2009; S. 256 Combat Methamphetamine Enhancement Act of 2009
Client expense: $1,046,127 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2010 · first_quarter · Pharmacy
H.R. 1204, the "Community Pharmacy Fairness Act of 2009", and S. 2161 Community Pharmacy Fairness Act from the 110th Congress; H.R. 616 and S. 511, the "Access to Durable Medical Equipment Act of 2009"; H.R. 1970 and S. 956, the "Preserve Patient Access to Reputable DMEPOS Providers Act of 2009"; H.R. 6331 (110th Congress), the "Medicare Improvements for Patients and Providers Act of 2008." Sec. 154 related to Medicare DMEPOS competitive acquisition program; and Sec. 172, related to submission of claims by pharmacies located in or contracting with long-term care facilities; Sec. 203, related to pharmacy payment under Medicaid; H.R. 1, "American Recovery and Reinvestment Act - P.L. 111-5 -- provisions related to Health Information Technology and HIPPA requirements; H.R. 5839 of the 110th Congress, the "Safeguarding America's Pharmaceuticals Act of 2008", provision relating to pedigree and track and trace requirements; H.R. 1427, the "Promoting Innovation and Life Savings Medicines Act of 2009"; H.R. 2647 and S. 1390, National Defense Authorization Act for 2010-Provides for the funding for the Department of Defense for fiscal year 2010-including the Tricare pharmacy program; H.R. 3108, the "Medication Therapy Benefits Act of 2009"; S. 1649, the "Weapons of Mass Destruction (WMD) Prevention and Preparednesss Act of 2009, pharmacy provider provisions; S. 1383, the "Dextromethorphan Abuse Reduction Act; H.R.3663: To amend title XVIII of the Social Security Act to delay the date on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies; H.R. 2891, the "Access to Frontline Health Care Act of 2009"; H.R. 3200, the "America's Affordable Health Choices Act of 2009"; the draft Senate HELP Committee's "Affordable Health Choices Act of 2009"; Senate Finance Committee draft health care reform bill, all provisions related to Medicaid AMP pharmacy reimbursement, Medicare Part B DMEPOS accreditation and surety bond requirements, medication therapy management, public plan option and pharmacy benefit manager transparency requirements; H.R.3590: An act entitled The Patient Protection and Affordable Care ActDME Accreditation, AMP Fix, PBM Transparency, MTM Expansion, OPM PBA v. PBM; Senator Akaka Amendment to Senate version of H.R. 3590 to establish automatic enrollment into a Medicare Part D "chronic care management" program for targeted individuals; Senator Brown amendment to H.R. 3590 eliminating DMEPOS surety bond requirement for retail pharmacies; Senator Dorgan Drug Reimportation amendment to H.R. 3590; FSA Debit Card Programseeking Congressional support to amend IRS guidance (no legislation). P.L. 110-275, the Medicare Improvements for Patients and Providers Act of 2008, implementation of Part D prompt payment and Part B DMEPOS provisions; H.R. 4213, American Workers, State, and Business Relief Act of 2010, section 213, Medicare Part B DMEPOS accreditation requirements; H.R. 4872 and substitute amendment to H.R. 4872, the Health Care and Education Affordability Reconciliation Act of 2010, section 1101, the Medicare Part D "donut hole", section 1305, oversight of DMEPOS suppliers.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
2010 · first_quarter · Alcohol and Drug Abuse
HR 1259, Dextromethorphan Distribution Act, restrictions on distribution of bulk Dextromethorphan. S. 1383, Dextromethorphan Abuse Reduction Act of 2009; Amendment to Controlled Substances Act to prevent abuse of Dextromethorphan and to impose age restrictions. Electronic tracking for pseudoephedrine - No bills.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $6,200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · fourth_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $5,590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · fourth_quarter · Consumer Issues/Safety/Products
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
Client expense: $5,590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)
2009 · fourth_quarter · Law Enforcement/Crime/Criminal Justice
HR 1173, Organized Retail Crime Act of 2009 - Organized Retail Crime S. 470, Combating Organized Retail Crime Act of 2009 - Organized Retail Crime HR 1166, E-fencing Enforcement Act of 2009 - Organized Retail Crime S. 1383, Dextromethorphan Abuse Reduction Act
Client expense: $880,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Federal Reserve System, Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2009 · fourth_quarter · Consumer Issues/Safety/Products
HR 1259 the Dextromethorphan Distribution Act of 2009 all provisions of the bill; regarding amending the federal food, drug, and cosmetic act to limit the distribution and abuse of DXM. HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug Safety provisions relating to country of origin labeling for drugs and devices. HR. 1548 the Pathway for Biosimilars Act all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals. S. 726/HR. 1427 the Promoting Innovation and Access to Life-Saving Medicine Act - all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals. HR. 1815 the Consumer Product Safety Solutions Act Section 2 provision relating to lead limits and third party testing requirements, Section 3 provisions relating to phthalates prohibition, Section 4 provisions relating to clarification of testing methodologies, Section 5 provisions relating to the exclusion of certain materials from lead content limit, Section 6 provision relating to the waiver of third party testing requirements for certain component parts, Section 7 provisions relating to exemptions from tracing label requirements, Section 8- provisions relating to the general application and exemptive authority of the Consumer Product Safety Commission. S. 882 the Drug and Device Accountability Act of 2009 Title I Ensuing the safety and quality of medical products and their components all provisions relating to this title on drug and device safety. S. 1383 the Dextromethorphan Abuse Reduction Act of 2009 all provisions; regarding amending the Controlled Substances Act to prevent the abuse of dextromethorphan.
Client expense: $430,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
2009 · fourth_quarter · Consumer Issues/Safety/Products
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions.
Client expense: $1,640,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of